Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Antonio Jimeno, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

The EGFR is a validated anticancer target whose successful exploitation has added novel agents to our current treatment protocols. Subsets of patients have shown to benefit the most from these therapies, and though these differential responses have yet to be completely defined, they are mostly of genetic nature. Egfr amplifications have shown to increase sensitivity to both small molecule inhibitors and specific monoclonal antibodies targeting the EGFR. A somatic/germline egfr intron 1 CA repeat sequence polymorphism has shown to have an important role in the control of EGFR protein expression, and has been linked to an increased risk of familial breast cancer, a worse outcome in patients with colorectal cancer, and anti-EGFR treatment efficacy in preclinical models. Egfr activating mutations have been recently described in lung cancer linking a cluster of genotypes with sensitivity to EGFR tyrosine kinase pharmacological inhibition. Despite the initial excitement that this discovery elicited, follow-up reports have not unequivocally confirmed this finding, and these drugs have been solidly efficacious both in individual patients and in diseases generally lacking egfr mutations such as pancreas cancer. We are witnessing exciting developments in the field of the pharmacogenomics of cancer, and this has particularly evolved in the area pertaining EGFR tyrosine kinase inhibitors. This review will discuss the background and currently available preclinical and clinical data.

Original languageEnglish (US)
Pages (from-to)217-229
Number of pages13
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1766
Issue number2
DOIs
StatePublished - Dec 2006

Fingerprint

Pharmacogenetics
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
Clinical Protocols
Pancreatic Neoplasms
Introns
Colorectal Neoplasms
Lung Neoplasms
Genotype
Monoclonal Antibodies
Pharmacology
Pharmaceutical Preparations
Neoplasms
Proteins

Keywords

  • EGFR
  • Pharmacogenomics
  • Targeted therapies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Biophysics
  • Medicine(all)

Cite this

Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. / Jimeno, Antonio; Hidalgo, Manuel.

In: Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1766, No. 2, 12.2006, p. 217-229.

Research output: Contribution to journalArticle

@article{adb76da5ece345c7a59ee431347bf08a,
title = "Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors",
abstract = "The EGFR is a validated anticancer target whose successful exploitation has added novel agents to our current treatment protocols. Subsets of patients have shown to benefit the most from these therapies, and though these differential responses have yet to be completely defined, they are mostly of genetic nature. Egfr amplifications have shown to increase sensitivity to both small molecule inhibitors and specific monoclonal antibodies targeting the EGFR. A somatic/germline egfr intron 1 CA repeat sequence polymorphism has shown to have an important role in the control of EGFR protein expression, and has been linked to an increased risk of familial breast cancer, a worse outcome in patients with colorectal cancer, and anti-EGFR treatment efficacy in preclinical models. Egfr activating mutations have been recently described in lung cancer linking a cluster of genotypes with sensitivity to EGFR tyrosine kinase pharmacological inhibition. Despite the initial excitement that this discovery elicited, follow-up reports have not unequivocally confirmed this finding, and these drugs have been solidly efficacious both in individual patients and in diseases generally lacking egfr mutations such as pancreas cancer. We are witnessing exciting developments in the field of the pharmacogenomics of cancer, and this has particularly evolved in the area pertaining EGFR tyrosine kinase inhibitors. This review will discuss the background and currently available preclinical and clinical data.",
keywords = "EGFR, Pharmacogenomics, Targeted therapies, Tyrosine kinase inhibitors",
author = "Antonio Jimeno and Manuel Hidalgo",
year = "2006",
month = "12",
doi = "10.1016/j.bbcan.2006.08.008",
language = "English (US)",
volume = "1766",
pages = "217--229",
journal = "Biochimica et Biophysica Acta - Reviews on Cancer",
issn = "0304-419X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

AU - Jimeno, Antonio

AU - Hidalgo, Manuel

PY - 2006/12

Y1 - 2006/12

N2 - The EGFR is a validated anticancer target whose successful exploitation has added novel agents to our current treatment protocols. Subsets of patients have shown to benefit the most from these therapies, and though these differential responses have yet to be completely defined, they are mostly of genetic nature. Egfr amplifications have shown to increase sensitivity to both small molecule inhibitors and specific monoclonal antibodies targeting the EGFR. A somatic/germline egfr intron 1 CA repeat sequence polymorphism has shown to have an important role in the control of EGFR protein expression, and has been linked to an increased risk of familial breast cancer, a worse outcome in patients with colorectal cancer, and anti-EGFR treatment efficacy in preclinical models. Egfr activating mutations have been recently described in lung cancer linking a cluster of genotypes with sensitivity to EGFR tyrosine kinase pharmacological inhibition. Despite the initial excitement that this discovery elicited, follow-up reports have not unequivocally confirmed this finding, and these drugs have been solidly efficacious both in individual patients and in diseases generally lacking egfr mutations such as pancreas cancer. We are witnessing exciting developments in the field of the pharmacogenomics of cancer, and this has particularly evolved in the area pertaining EGFR tyrosine kinase inhibitors. This review will discuss the background and currently available preclinical and clinical data.

AB - The EGFR is a validated anticancer target whose successful exploitation has added novel agents to our current treatment protocols. Subsets of patients have shown to benefit the most from these therapies, and though these differential responses have yet to be completely defined, they are mostly of genetic nature. Egfr amplifications have shown to increase sensitivity to both small molecule inhibitors and specific monoclonal antibodies targeting the EGFR. A somatic/germline egfr intron 1 CA repeat sequence polymorphism has shown to have an important role in the control of EGFR protein expression, and has been linked to an increased risk of familial breast cancer, a worse outcome in patients with colorectal cancer, and anti-EGFR treatment efficacy in preclinical models. Egfr activating mutations have been recently described in lung cancer linking a cluster of genotypes with sensitivity to EGFR tyrosine kinase pharmacological inhibition. Despite the initial excitement that this discovery elicited, follow-up reports have not unequivocally confirmed this finding, and these drugs have been solidly efficacious both in individual patients and in diseases generally lacking egfr mutations such as pancreas cancer. We are witnessing exciting developments in the field of the pharmacogenomics of cancer, and this has particularly evolved in the area pertaining EGFR tyrosine kinase inhibitors. This review will discuss the background and currently available preclinical and clinical data.

KW - EGFR

KW - Pharmacogenomics

KW - Targeted therapies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33847359176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847359176&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2006.08.008

DO - 10.1016/j.bbcan.2006.08.008

M3 - Article

C2 - 17045403

AN - SCOPUS:33847359176

VL - 1766

SP - 217

EP - 229

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

SN - 0304-419X

IS - 2

ER -